Screening the p53 status of human cell lines using a yeast functional assay

Molecular Carcinogenesis

Volumn 19, Issue 4, 1997, Pages 243-253

  Jia, Li Qun ^a,b   Osada, Motonobu ^a   Ishioka, Chikashi ^a   Gamo, Makio ^a   Ikawa, Shuntaro ^a   Suzuki, Takao ^a   Shimodaira, Hideki ^a   Niitani, Tomohito ^a   Kudo, Toshio ^a   Akiyama, Mitoshi ^c   Kimura, Narimiti ^d   Matsuo, Mitsuyoshi ^d   Mizusawa, Hiroshi ^e   Tanaka, Noriho ^f   Koyama, Hideki ^g   Namba, Masayoshi ^h   Kanamaru, Ryunosuke ^a   Kuroki, Toshio ⁱ  

^a TOHOKU UNIVERSITY   (Japan)

^b CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^c RADIATION EFFECTS RESEARCH FOUNDATION   (Japan)

^d TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^e NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^f HATANO RESEARCH INSTITUTE   (Japan)

^g YOKOHAMA CITY UNIVERSITY   (Japan)

^h OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

ⁱ SHOWA UNIVERSITY   (Japan)

Author keywords

Carcinogenesis; Immortalization; p53; Temperature sensitive mutation; Tumor suppressor gene

Indexed keywords

COMPLEMENTARY DNA; PROTEIN P53;

ALLELE; ARTICLE; GENE FREQUENCY; GENE MUTATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; SACCHAROMYCES CEREVISIAE; TEMPERATURE SENSITIVITY; TRANSACTIVATION;

ALLELES; GENES, P53; GENETIC SCREENING; HUMANS; MUTATION; NEOPLASMS; RNA, MESSENGER; SACCHAROMYCES CEREVISIAE; SENSITIVITY AND SPECIFICITY; TEMPERATURE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

SACCHAROMYCES CEREVISIAE;

EID: 0030817069     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D     Document Type: Article

References (59)

1. Fields S, Jang SK. Presence of a potent transcription activating sequence in the p53 protein. Science 249:1045-1049, 1990.
2. Raycroft L, Wu HY, Lozano G. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 249:1049-1051, 1990.
3. Kastan MB, Zhan Q, El-Deiry WS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia telangiectasia. Cell 71:587-597, 1992.
4. El-Deiry W, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825, 1993.
5. Dulic V, Kaufmann WK, Wilson SJ, et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76:1013-1023, 1994.
6. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299, 1995.
7. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 379:88-91, 1996.
8. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89:7491-7495, 1992.
9. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967, 1993.
10. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 253:49-53, 1991.
11. O'Connor PM, Jackman J, Jondle D, Bhatia K, Magrath I, Kohn KW. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res 53:4776-4780, 1993.
12. Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331:1259-1264, 1994.
13. Wattel E, Preudhomme C, Hecquet B, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84:3148-3157, 1994.
14. Nishio M, Koshikawa T, Kuroishi T, et al. Prognostic significance of abnormal p53 accumulation in primary, resected non-small cell lung cancer. J Clin Oncol 14:497-502, 1996.
15. Shogren S, Inganas M, Norberg T, et al. The p53 gene in breast cancer: Prognostic value of complementary DMA sequencing versus immunohistochemistry. J Natl Cancer Inst 88:173-182, 1996.
16. Ishioka C, Frebourg T, Yan YX, et al. Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat Genet 5:124-129, 1993.
17. Flaman JM, Frebourg T, Moreau V, et al. A rapid PCR fidelity assay. Nucleic Acids Res 22:3259-3260, 1994.
18. Flarnan JM, Frebourg T, Moreau V, et al. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 92:3963-3967, 1995.
19. Ishioka C, Englert C, Winge P, Yan YX, Engelstein M, Friend SH. Mutational analysis of the carboxy-terminal portion of p53 using both yeast and mammalian cell assays in vivo. Oncogene 10:1485-1492, 1995.
20. Yamada Y, Yoshida T, Hayashi K, et al, p53 gene mutations in gastric cancer metastases and in gastric cancer cell lines derived from metastases. Cancer Res 51:5800-5805, 1991.
21. Bressac B, Galvin KM, Liang TJ, Isselbacher KJ, Wands JR, Ozturk M. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc Natl Acad Sci USA 87:1973-1977, 1990.
22. Wolf D, Rotter V. Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc Natl Acad Sci USA 82:790-794, 1985.
23. 60Co gamma rays. Int J Cancer 66:698-702, 1996.
24. Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer: Mutation and nuclear exclusion. Proc Natl Acad Sci USA 89:7262-7266, 1992.
25. Moll U, LaGuaglia M, Benard J, Riou G. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastoma. Proc Natl Acad Sci USA 92:4407-4411, 1995.
26. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136, 1992.
27. Ory K, Legros Y, Auguin C, Soussi T. Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J 13:3496-3504, 1994.
28. Crook T, Marston NJ, Sara EA, Vousden KH. Transcriptionsl activation by p53 correlates with suppression of growth but not transformation. Cell 79:817-827, 1994.
29. Rowan S, Ludwig RL, Haupt Y, Bates S, Lu X, Oren M, Vousden KH. Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J15:827-838, 1996.
30. Haupt Y, Rowan S, Shaulian E, Vousden KH, Oren M. Induction of apoptosisin HeLa cells by frans-activation-deficient p53. Genes Dev 9:2170-2183, 1995.
31. Milner J, Medcalf EA. Temperature-dependent switching between "wild-type" and "mutant" forms of p53-Val135. J Mol Biol 216:481-484, 1990.
32. Scharer E, Iggo R. Mammalian p53 can function as a transcription factor in yeast. Nucleic Acids Res 20:1539-1545, 1992.
33. Friend SH. p53: A glimpse at the puppet behind the shadow play. Science 265:334-335, 1994.
34. Wills KN, Maneval DC, Menzel P, et al. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther 5:1079-1088, 1994.
35. Clayman GL, el-Naggar AK, Roth JA, et al. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 55:1-6, 1995.
36. Katayose D, Gudas J, Nguyen H, Srivastava S, Cowan KH, Seth P. Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells. Clin Cancer Res 1:889-897, 1995.
37. Gomez-Manzano C, Fueyo J, Kyritsis AP, et al. Adeno-virus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res 56:694-699, 1996.
38. Roth JA, Nguyen D, Lawrence DD, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 2:985-991, 1996.
39. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274:373-376, 1996.
40. Sheng G, El-Deiry WS. p53 and chemosensitivity. Nat Med 2:255-256, 1996.
41. Hollstein MC, Peri L, Mandard AM, et al. Genetic analysis of human esophageal tumors from two high incidence geographic areas: Frequent p53 base substitutions and absence of ras mutations. Cancer Res 51:4102-4106, 1991.
42. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 342:705-708, 1989.
43. Rodrigues NR, Rowan A, Smith ME, et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 87:7555-7559, 1990.
44. Yaginuma Y, Westphal H. Analysis of the p53 gene in human uterine carcinoma cell lines. Cancer Res 51:6506-6509, 1991.
45. Harlow E, Williamson NM, Ralston R, Helfman DM, Adams TE. Molecular cloning and in vitro expression of a cDNA clone for human cellular tumor antigen p53. Mol Cell Biol 5:1601-1610, 1985.
46. Caamano J, Zhang SY, Rosvold EA, Bauer B, Klein S-A. p53 alterations in human squamous cell carcinomas and carcinoma cell lines. Am J Pathol 142:1131-1139, 1993.
47. Matozaki T, Sakamoto C, Matsuda K, et al. Missense mutations and a deletion of the p53 gene in human gastric cancer. Biochem Biophys Res Commun 182:215-223, 1992.
48. Sakai E, Tsuchida N. Most human squamous cell carcinomas in the oral cavity contain mutated p53 tumor-suppressor genes. Oncogene 7:927-933, 1992.
49. Hsu IC, Tokiwa T, Bennett W, et al. p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis 14:987-992, 1993.
50. Murakami Y, Hayashi K, Sekiya T. Detection of aberrations of the p53 afleles and the gene transcript in human tumor cell lines by single-strand conformation polymorphism analysis. Cancer Res 51:3356-3361, 1991.
51. Cheng J, Haas M. Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol Cell Biol 10:5502-5509, 1990.
52. Sugimoto K, Toyoshima H, Sakai R, et al. Frequent mutations in the p53 gene in human myeloid leukemia cell lines. Blood 79: 2378-2383, 1992.
53. Yaginuma Y, Westphal H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 52:4196-4199, 1992.
54. Feinstein E, Cimino G, Gale RP, et al. p53 in chronic myelogenous leukemia in acute phase. Proc Natl Acad Sci USA 88:6293-6297, 1991.
55. Kashii T, Mizushima Y, Monno S, Nakagawa K, Kobayashi M. Gene analysis of K-, H-ras, p53, and retinoblastoma susceptibility genes in human lung cancer cell lines by the polymerase chain reaction/single-strand conformation polymorphism method. J Cancer Res Clin Oncol 120:143-148, 1994.
56. Mazars G-R, Portier M, Zhang X-G, et al. Mutations of the p53 gene in human myeloma cell lines. Oncogene 7:1015-1018, 1992.
57. Ruggeri B, Zhang SY, Caamano J, DiRado M, Flynn SD, Klein S-A. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes. Oncogene 7:1503-1511, 1992.
58. Yoshtmoto K, Iwahana H, Fukuda A, Sano T, Saito S, Itakura M. Role of p53 mutations in endocrine tumorigenesis: Mutation detection by polymerase chain reaction-single strand conformation polymorphism. Cancer Res 52:5061-5064, 1992.
59. Lehman TA, Modali R, Boukamp P, et al. p53 mutations in human immortalized epithelial cell lines [published erratum appears in Carcinogenesis 14:1491 1993]. Carcinogenesis 14:833-839, 1993.